Payer Communications Safe Harbor Should Extend To Off-Label Uses – Industry

US FDA should apply same regulatory protections to manufacturer communications with payers about unapproved uses that agency draft guidance provides to information exchanges about investigational products, biopharma companies say.

Drug manufacturer communications to payers about off-label uses of approved products should be protected from US FDA enforcement if those uses are being actively studied or undergoing regulatory review, biopharma companies say.

In comments on FDA’s draft guidance on payer communications, industry groups and individual companies urge FDA to provide information exchanges...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Marketing & Advertising

India And Pakistan Boost Transparency In Industry-Doctor Interactions

 
• By 

Developments in India and Pakistan are designed to standardize how drug companies disclose their expenses associated with health care professionals.

Celebs Bring Extra Scrutiny To Advertisements, US FDA Tells AbbVie

 

AbbVie’s migraine ad overstates the drug’s benefit, a problem that is amplified by using a celebrity, the agency says. 

Misconstruing Single-Arm Study Data Lands BMS In Trouble With US FDA

 

The lung cancer drug Krazati from Bristol Myers Squibb’s Mirati Therapeutics drew an FDA ad/promo untitled letter, highlighting the agency's trend of pursuing false or misleading efficacy claims, particularly when data comes from outside approved labeling.

Severe Misconduct, Repeat Offending And Underreporting: UK/EU Codes Come Under Fire

 

The UK and EU pharma industry associations have defended their respective codes of practice despite alarming study results. Meanwhile, a consultation on proposals to revise the UK code received over 3,500 comments.

More from Compliance

HTA Regulation: EU Publishes Guidance On Validity Of Clinical Studies For Joint Clinical Assessments

 

Joint clinical assessment reports must be descriptive rather than reach definitive conclusions, and must not interfere with national decision making processes, according to new EU guidance.

India And Pakistan Boost Transparency In Industry-Doctor Interactions

 
• By 

Developments in India and Pakistan are designed to standardize how drug companies disclose their expenses associated with health care professionals.

Draft US FDA Innovative Manufacturing Strategy Takes On Global Inconsistency

 

The agency’s plan for advanced manufacturing seeks more harmonization, while also seeking to codify internal practices with guidance and training.